1. Home
  2. MDAI vs TCRX Comparison

MDAI vs TCRX Comparison

Compare MDAI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MDAI

Spectral AI Inc.

HOLD

Current Price

$1.41

Market Cap

48.8M

Sector

Health Care

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDAI
TCRX
Founded
2013
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.8M
57.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
MDAI
TCRX
Price
$1.41
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$3.25
$8.50
AVG Volume (30 Days)
215.5K
447.1K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
$286.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$1.04
$0.88
52 Week High
$3.21
$2.57

Technical Indicators

Market Signals
Indicator
MDAI
TCRX
Relative Strength Index (RSI) 39.75 51.76
Support Level $1.32 $0.90
Resistance Level $1.76 $1.23
Average True Range (ATR) 0.07 0.08
MACD -0.01 0.01
Stochastic Oscillator 29.17 63.10

Price Performance

Historical Comparison
MDAI
TCRX

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: